Pharmacy No. 84. Delivery of medicines to your home and office.

Delivery on Sundays and holidays does not work!

Medicines

my basket

Apteka84.kz is an online pharmacy that offers its customers medicines, medicinal and decorative cosmetics, dietary supplements, vitamins, baby food, intimate products for adults, medical equipment and thousands of other medical and cosmetic products at low prices. All data presented on the Apteka84.kz website is for informational purposes only and is not a substitute for professional medical care. Apteka84.kz strongly recommends that you carefully read the instructions for use contained in each package of medicines and other products. If you currently have any symptoms of the disease, you should seek help from a doctor. You should always tell your doctor or pharmacist about all the medicines you take. If you feel you need further help, please consult your local pharmacist or contact our GP online or by telephone.

Genferon Light nasal drops 10000IU/ml+0.8 mg/ml fl.10ml

A country

Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.

Compound

Bottle 10 mlInterferon alpha-2b 10000 IU, taurine 0.8 mg.

pharmachologic effect

The drug Genferon Light, nasal drops, has antiviral, immunomodulatory, anti-inflammatory, antiproliferative, antibacterial effects, has local regenerating, membrane-stabilizing and antioxidant properties. Interferon alpha blocks the proliferation of viruses at the stage of synthesis of specific proteins and prevents infection of uninfected cells of the nasal mucosa, which is the site of pathogen invasion and the primary focus of inflammation during respiratory infections. The immunomodulatory effect is manifested by an increase in cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against foreign agents. This is achieved through the activation of CD8+ T-killers, NK cells (natural killer cells), increased differentiation of B-lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the main histocompatibility complex type 1, which increases the likelihood recognition of infected cells by cells of the immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced by the iodine influence of interferon. Taurine, which is part of the drug, normalizes metabolic processes in tissues, promotes regeneration and faster restoration of the nasal mucosa, damaged by the pathological process.

Indications for use

Treatment of influenza and other acute respiratory viral infections in children aged 29 days to 14 years.

Mode of application

At the first signs of the disease, Genferon Light is instilled into the nose for 5 days. Children from 29 days to 11 months 29 days - 1 drop in each nasal passage 5 times a day (single dose 1,000 IU, daily dose 5,000 IU). Children from 1 to 3 years old - 2 drops in each nasal passage 3-4 times a day (single dose 2,000 IU. daily dose 6,000-8,000 IU). Children from 3 to 14 years old - 2 drops in each nasal passage 4- 5 times a day (single dose 2,000 IU, daily dose - 8,000-10,000 IU).

Interaction

The simultaneous use of intranasal vasoconstrictor drugs is not recommended, as this causes additional dryness of the nasal mucosa.

Side effect

Local allergic reactions (burning sensation, itching) are possible. These phenomena are reversible and disappear on their own within 72 hours after stopping the use of the drug. Continuation of treatment is possible only after consultation with a doctor.

Contraindications

- hypersensitivity to interferon alfa-2b or other components of the drug; - newborns from 0 to 28 days (due to the lack of clinical data).

Overdose

Cases of overdose of the drug Genferon Light have not been registered to date.

special instructions

After instillation, it is recommended to massage the wings of the nose with your fingers for several minutes to evenly distribute the drug in the nasal cavity. Effect on the ability to drive vehicles and operate machinery. The effect of the drug Genferon Light on the performance of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machine equipment, etc.) have not been studied.

Dispensing conditions in pharmacies

On prescription

Genferon light Spray, 100 d, 50000 IU, nasal

Description

Genferon Light spray is the only antiviral nasal spray for the treatment and prevention of ARVI and influenza with a maximum dose of the active substance* for adults and children over 14 years of age.
Approved for use in pregnant women. Genferon Light spray - maximum 1 dose. Comfortable, modern, convenient.

Genferon Light is the only combination of interferon and taurine** in Russia for the treatment and prevention of ARVI and influenza. Tested in 9 large clinical studies on 1579 patients.

Advantages of the drug Genferon Light spray.

1. Actively fights viruses and bacteria at the site of their invasion - the nasal cavity.

2. Has a universal antiviral effect.

3. Activates protective local immunity.

4. Contains glycerol*****, known for its moisturizing properties***,****.

5. Contains mint oil*****

Advantages of the release form.

1. The dosed spray nozzle Genferon Light in the form of a spray ensures comfortable use and dose accuracy: 1 press - 1 dose of 50 thousand IU of the drug

2. Genferon Light in the form of a spray provides a fine (“fog-like”) spray of the drug to create an even distribution over the entire surface of the nasopharynx, helping to block viral invasion.

3. The special design of the bottle with a pump ensures full use of the antiviral agent without residue.

4. Cost-effectiveness of Genferon Light spray: one bottle of antiviral spray contains 100 doses. Can be used for several episodes of colds or for prevention throughout the cold season.

5. An opened bottle of Genferon Light can be used until the end of the drug’s shelf life.

6. Can be combined with other drugs (symptomatic, etiotropic).

7. The spray form is not characterized by stomach side effects typical of oral medications.

*The maximum dosage of IFN alpha 2b is 50,000 IU in 1 dose, among nasal interferons, according to the GRLS March 2021.

**According to GRLS data March 2021.

***Raymond KR et al. Handbook of pharmaceutical excipients. Sixth edition. 2009 (Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Handbook of Pharmaceutical Excipients. Sixth edition. 2009).

****Marie Loudin et al. Dermatology: Clinical and Basic Science Series. Dry skin and moisturizers. Second edition. 2006 (Marie Loden, Howard I. Maibach. Dermatology: Clinical&Basic science series. Dry skin and moisturizers. Chemistry and Function. Second edition. 2006).

*****Auxiliary component.

Description

Transparent colorless or light yellow liquid, without visible mechanical inclusions.

Genferon Light spray, 1 piece, 50000 IU+1 mg/dose, dosed nasal spray

Vaginal or rectal suppositories:
vaginal, rectal.
The route of administration, dosage and course duration depend on age and the specific clinical situation. In adults and children over 7 years of age, Genferon® Light is used in a dosage of 250,000 IU of interferon alfa-2b per suppository. In children under 7 years of age, including infants, it is safe to use the drug at a dosage of 125,000 IU of interferon alfa-2b per suppository. In women who are 13–40 weeks pregnant, the drug is used at a dose of 250,000 IU of interferon alfa-2b per suppository.

Recommended dosages and treatment regimens

ARVI and other acute viral diseases in children:

1 sup. rectally 2 times a day with a 12-hour interval in parallel with the main therapy for 5 days. If, after a 5-day treatment period, the symptoms of the disease do not decrease or become more pronounced, the patient should consult a doctor. According to clinical indications, it is possible to repeat the course of treatment after a 5-day interval.

Chronic infectious and inflammatory diseases of viral etiology in children:

1 sup. rectally 2 times a day with a 12-hour interval simultaneously with standard therapy for 10 days. Then for 1–3 months - 1 sup. rectally at night every other day.

Acute infectious and inflammatory diseases of the urogenital tract in children:

1 sup. rectally 2 times a day with a 12-hour interval for 10 days, against the background of specific therapy prescribed and supervised by a doctor.

Infectious and inflammatory diseases of the urogenital tract in pregnant women:

1 sup. (250,000 IU) vaginally 2 times a day with a 12-hour interval for 10 days, against the background of specific therapy prescribed and supervised by a doctor.

Infectious and inflammatory diseases of the urogenital tract in women:

1 sup. (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day with a 12-hour interval for 10 days, against the background of specific therapy prescribed and supervised by a doctor. For prolonged forms, 3 times a week every other day, 1 sup. within 1–3 months.

Dosed nasal spray:
intranasally,
by aerosol administration of 1 dose (1 dose = 1 short press on the dispenser).

At the first signs of the disease, Genferon® Light is administered intranasally for 5 days, one dose (one press on the dispenser) into each nasal passage 3 times a day (one dose is approximately 50,000 IU of interferon alfa-2b, the daily dose should not exceed 500,000 IU).

In case of contact with a patient with acute respiratory viral infection and/or hypothermia, the drug is administered according to the indicated regimen 2 times a day for 5–7 days. If necessary, preventive courses are repeated.

Instructions for use of the spray

1. Remove the protective cap.

2. Before using for the first time, press the dispenser several times until a thin stream appears.

3. When using, keep the bottle in an upright position.

4. Inject the drug by pressing the dispenser once into each nasal passage in turn.

5. After use, close the dispenser with the protective cap.

To avoid the spread of infection, individual use is recommended.

Instructions for use GENFERON® (GENFERON)

A combined drug whose effect is determined by the components included in its composition. Has local and systemic effects.

The composition of the drug Genferon® includes recombinant human interferon alpha-2b, produced by a strain of the bacterium Escherichia coli, into which the human interferon alpha-2b gene was introduced using genetic engineering methods.

Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of CD8+ T killer cells, NK cells (natural killer cells), increased differentiation of B lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the major histocompatibility complex type I, which increases the likelihood recognition of infected cells by cells of the immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon.

Taurine helps normalize metabolic processes and tissue regeneration, has membrane-stabilizing and immunomodulatory effects. Being a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to the development of pathological processes. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug. Benzocaine (anesthetic) is a local anesthetic. Reduces the permeability of the cell membrane to sodium ions, displaces calcium ions from receptors located on the inner surface of the membrane, and blocks the conduction of nerve impulses. Prevents the occurrence of pain impulses at the endings of sensory nerves and their conduction along nerve fibers. It has an exclusively local effect, without being absorbed into the systemic circulation.